Nutramax cough/cold sales up 47% in second quarter; PFI third quarter sales jump 56.7%.
This article was originally published in The Tan Sheet
Executive Summary
NUTRAMAX COUGH/COLD SALES UP 47% TO $7.8 MIL. IN THE SECOND QUARTER ended March 29, the Gloucester, Mass.-based com-pany reported. The category comprised about 31% of the company's overall second quarter sales. The company noted that it had a "superb" cough/cold season; cough drop sales are "strong," Nutramax said, and contract manufacturing for the category (Celestial Seasonings and Whitehall's Robitussin) has been "increasing radically and dramatically."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning